Table 3.
Summary of study results
| Author | Year | Adverse events |
Single dose of perioperative intravesical therapy | Period | RR |
RFS (%) |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| PDD | WL | (mo) | PDD | WL | PDD | WL | ||||
| HAL | Hermann [23] | 2011 | Not reported | None | 12 | 18/59 | 35/74 | 69.5 | 52.7 | |
| Geavlete [24] | 2012 | Not reported | Mitomycin C | 12 | 27/125 | 37/114 | 78.4 | 67.5 | ||
| 24 | 39/125 | 52/114 | 68.8 | 54.4 | ||||||
| Karaolides [25] | 2012 | Not reported | Epirubicin | 12 | Not stated | 91 | 56.3 | |||
| O'Brien [17] | 2013 | None observed | Mitomycin C | 12 | 27/80 | 29/81 | 66.3 | 64.2 | ||
| Gkritsios [26] | 2014 | Not reported | Epirubicin | 12 | 7/48 | 7/37 | 85.4 | 81.1 | ||
| 24 | 12/48 | 14/37 | 75.0 | 62.2 | ||||||
| Drăgoescu [27] | 2017 | Not reported | Farmorubicin | 12 | 14/57 | 21/56 | 75.4 | 62.5 | ||
| 24 | 24/57 | 30/56 | 57.9 | 46.4 | ||||||
| 5-ALA | Filbeck [14] | 2002 | None observed | None | 12 | Not stated | 89.6 | 73.8 | ||
| 24 | 89.6 | 65.9 | ||||||||
| Babjuk [28] | 2005 | Not reported | None | 12 | Not stated | 66 | 39 | |||
| 24 | 40 | 28 | ||||||||
| Daniltchenko [29] | 2005 | Not reported | None | 12 | 22/51 | 31/51 | 56.9 | 39.2 | ||
| 24 | 28/51 | 34/51 | 45.1 | 33.3 | ||||||
| Schumacher [30] | 2010 | 28% | 17.5% | None | 12 | Not stated | 50.4 | 53.1 | ||
| Stenzl [31] | 2011 | 32.6% | 33.9% | None | 12 | Not stated | 64 | 72.8 | ||
| Rolevich [32] | 2017 | Serious only: | ∼50% given doxorubicin | 12 | Not stated | 89 | 85 | |||
| 1.2% | 2.2% | 24 | 86 | 72 | ||||||
5-ALA = 5-aminolaevulinic acid; HAL = hexaminolaevulinate; PDD = photodynamic diagnosis; RFS = recurrence-free survival; RR = recurrence rate; WL = white light.